Bank Of America Corp Nymox Pharmaceutical Corp Transaction History

Bank Of America Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.33 - $0.5 $116 - $177	354 Added 100.0%	708 $0
Q4 2022 Feb 10, 2023	SELL	$0.28 - $0.74 $255 - $674	-912 Reduced 72.04%	354 $0
Q3 2022 Nov 14, 2022	SELL	$0.22 - $0.61 $436 - $1,209	-1,982 Reduced 61.02%	1,266 $1,000
Q2 2022 Aug 12, 2022	SELL	$0.38 - $1.41 $2,338 - $8,675	-6,153 Reduced 65.45%	3,248 $1,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.0 $6,916 - $11,432	-5,716 Reduced 37.81%	9,401 $12,000
Q4 2021 Feb 08, 2022	SELL	$0.95 - $2.1 $6,807 - $15,048	-7,166 Reduced 32.16%	15,117 $20,000
Q3 2021 Nov 15, 2021	SELL	$1.3 - $2.23 $9,963 - $17,090	-7,664 Reduced 25.59%	22,283 $46,000
Q2 2021 Sep 13, 2021	BUY	$1.46 - $2.48 $43,722 - $74,268	29,947 New	29,947 $47,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.